SCHEMBL4164573

SCHEMBL4164573

NC(=O)c1ccc(Cc2cccc(F)c2)o1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 1/20 0.46
MAOB P27338 1/20 0.46
PARP10 Q53GL7 1/20 0.46
ALDH1A1 P00352 3/20 0.45
MAPT P10636 1/20 0.45
PARP1 P09874 1/20 0.45
SLC9A1 P19634 1/20 0.44
THRB P10828 1/20 0.43
NR4A1 P22736 1/20 0.43
NR4A2 P43354 1/20 0.43
NR4A3 Q92570 1/20 0.43
MEN1 O00255 1/20 0.43
HPGD P15428 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HCAR2 Q8TDS4 1/20 0.42
TP53 P04637 2/20 0.41
LMNA P02545 1/20 0.41
SLC1A1 P43005 2/20 0.41
MAPK8 P45983 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674508 0.85 ALDH1A1 (0.46) MAOBALDH1A1MAPTTHRBNR4A1
SCHEMBL4150589 0.80 PLA2G10 (0.56) ALDH1A1MAPTMEN1HPGDKMT2A
SCHEMBL4673578 0.78 NR4A1 (0.41) MAOBALDH1A1MAPTTHRBNR4A1
SCHEMBL4673573 0.78 NR4A1 (0.41) MAOBALDH1A1MAPTTHRBNR4A1
SCHEMBL1680634 0.78 TAAR1 (0.50) NR3C2MAOB
SCHEMBL6671019 0.75 NR4A1 (0.74) ALDH1A1SLC9A1NR4A1NR4A2NR4A3
SCHEMBL4498539 0.74 TAAR1 (0.50) MAOBMAPTMEN1KMT2ATP53
SCHEMBL1680877 0.74 ALDH1A1 (0.46) MAOBALDH1A1SMN1; SMN2HCAR2LMNA
SCHEMBL27809629 0.73 MAPK8 (0.50) NR3C2MAOBPARP10PARP1HCAR2
SCHEMBL4159536 0.72 MAOB (0.45) NR3C2MAOBPARP10PARP1HCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-09-10 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
EP-1782811-A1 NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-05-09 EP disclosed
EP-1669348-A1 NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 2006-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound XPO1, THPO, G6PD NR3C2 3790/4885MAOB 2220/4885PARP10 796/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 NR3C2 2663/4885MAOB 1205/4885PARP10 3140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.